Observational studyFrontiers in immunology2026
Tolerability of immunoglobulin products and outcomes after product switching: a single-center real-world retrospective study.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We assessed the frequency of adverse drureactions (ADRs) to immunoglobulin products, associated switching patterns, and tolerability after switching in clinical practice. Methods: This observational, retrospective study was conducted at a single center. We included all patients who were treated with immunoglobulin therapy, irrespective of indication, between June 2017 and May 2025. Data on demographics, diagnoses, immunoglobulin received, ADRs, need for switching, and post-switch ADRs were extracted from records. Analyses were mainly descriptive. Results: We included 51 patients with a median (Q1, Q3) age of 54 (40, 63) years, mostly with primary or secondary immunodeficiencies, who were treated with intravenous immunoglobulins (IVIGs; n = 43) or subcutaneous immunoglobulins (SCIGs; n = 8). Among 42 patients treated with intravenous (IV) Flebogamma Conclusion: ADRs associated with IVIG are common and lead to treatment switching in a high proportion of patients. Switching to an alternative immunoglobulin product appears to be a good alternative for managing ADRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.